7月22日，Arrowhead Research Corporation盘中上涨19.25%，报89.54美元/股，成交额1.14亿美元。
消息面上，公司公布核心药物Plozasiran在两项关键后期临床试验Shasta-3和Shasta-4中成功达到主要终点，分别实现79%和81%的中位甘油三酯降低率；在高危患者群体中实现急性胰腺炎事件100%的风险削减，且安全性特征稳定，未出现新安全信号。
Plozasiran此前已以商品名Redemplo获得欧盟上市许可，用于治疗家族性乳糜微粒血症综合征。此次多项积极数据进一步拓宽其在心血管代谢疾病领域的适应症前景，多家机构给予买入评级，平均目标价91.82美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.